key: cord-0317076-ffl96t8m
authors: Bezzerri, Valentino; Gentili, Valentina; Api, Martina; Finotti, Alessia; Papi, Chiara; Tamanini, Anna; Olioso, Debora; Duca, Martina; Tedesco, Erika; Leo, Sara; Borgatti, Monica; Volpi, Sonia; Pinton, Paolo; Cabrini, Giulio; Gambari, Roberto; Blasi, Francesco; Lippi, Giuseppe; Rimessi, Alessandro; Rizzo, Roberta; Cipolli, Marco
title: ACE2 expression and localization are regulated by CFTR: implications beyond cystic fibrosis
date: 2021-11-22
journal: bioRxiv
DOI: 10.1101/2021.11.19.469220
sha: cd065800060d3bf3894b8bf40429206489e79f6a
doc_id: 317076
cord_uid: ffl96t8m

As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis (CF) could be considered a comorbidity for coronavirus disease 2019 (COVID-19)1. Instead, CF seems to constitute an advantage in COVID-19 infection2-5. To clarify whether host factors expressed by the CF epithelia may influence COVID-19 progression, we investigated the expression of SARS-CoV-2 receptor and coreceptors in primary airway epithelial cells. We found that angiotensin converting enzyme 2 (ACE2) expression and localization are regulated by cystic fibrosis transmembrane conductance regulator (CFTR) channels. Consistently, our results indicate that dysfunctional CFTR channels alter susceptibility to SARS-CoV-2 infection, resulting in reduced viral infection in CF cells. Depending on the pattern of ACE2 expression, the SARS-CoV-2 spike (S) protein induced high levels of Interleukin (IL)-6 in healthy donor-derived primary airway epithelial cells but a very weak response in primary CF cells. Collectively, these data support the hypothesis that CF condition is unfavorable for SARS-CoV-2 infection.

viral and cellular membranes 6 . SARS-CoV-2 infection primarily targets the airway epithelia. In some cases, infection leads to bilateral pneumonia with diffuse alveolar damage, which in turn may promote acute respiratory distress syndrome (ARDS), especially in subjects with comorbidities. Moreover, the onset of a cytokine storm, during which interleukin (IL)-6 plays a key role in morbidity, has been described in subcohorts of COVID-9 patients with poor prognosis 9, 10 . CD13 is a transmembrane metalloprotease coregulated with ACE2 in various primate and human tissues 11 that has also recently been proposed as a potential coreceptor of SARS-CoV-2 involved in viral entry and immune response 12 . Importantly, CD13 activation has been associated with the release of high levels of IL-6 in different cell models [13] [14] [15] .

CF is caused by mutations in the CFTR gene, which encodes a chloride and bicarbonate channel widely expressed in human epithelia. Loss of CFTR expression or function in airway epithelia is associated with reduced airway surface liquid (ASL) volume and dehydration. This process has been suggested as the initiating event of CF airway disease pathogenesis, which is characterized by severe impairment of lung function 16 . CF could therefore be considered an unfavorable comorbidity in patients with COVID-19, particularly considering that other respiratory viral infections, including respiratory syncytial virus (RSV) and influenza A (H1N1), lead to a rapid deterioration of lung function and increased mortality in CF patients 17, 18 .

However, several studies conducted on Belgian 2 , French 5 , Spanish 4 and Italian 19 cohorts of CF patients have reported that CF seems to protect against COVID-19. Even though age distribution has been proposed as a major confounding factor for incidence calculation in these studies 20 , the European Society of Cystic Fibrosis (ECFS) recently concluded that the case fatality rate associated with COVID-19 in CF patients was lower than in the general population. On the other hand, considering data that emerged from the French and Italian cohorts, it should not be dismissed that post lung transplant patients exhibited more severe manifestations in response to COVID-19 5, 19 .

Since 51.2% of patients registered in the ECFS patient registry are adults 20 , the possibility that the favorable COVID-19 disease outcome could be dependent only on pediatric age is questionable. Therefore, our hypothesis was that some specific host factors associated with CF may influence susceptibility to SARS-CoV-2 infection. Interestingly, it has been recently reported that TMEM16F, a Ca 2+ -activated chloride channel, plays a key role in SARS-CoV-2 viral entry and syncytia formation in lung epithelial cells 21 , may be actively involved in the pathogenesis of COVID-19. Furthermore, it has already been established that CFTR can regulate other apical proteins, including the ion channel solute carrier family 26 member 9 (SLC26A9) 22 , the epithelial sodium channel (ENaC) 23 , the potassium channel KIR 1.1 24 , Phosphatase And Tensin Homolog protein (PTEN) 25 , and receptors such as the A2B adenosine receptor 26 . These regulatory functions of CFTR might be due to direct binding of CFTR to other proteins or indirect binding through PDZ-interacting domains through the adapter proteins ezrin, Na + /H + exchanger regulatory factor (NHERF)1 and NHERF2. Given all of these possibilities, we investigated the role of CFTR in regulating SARS-CoV-2 receptors and coreceptors.

We first explored the expression of ACE2, TMRPSS2, and CD13 in CF primary airway epithelial cells. ACE2 mRNA expression was reduced in both primary bronchial epithelial cells (HBECs) and nasal epithelial cells (HNECs) isolated from CF patients homozygous for the F508del CFTR mutation (Supplementary Table 1 ) compared to healthy donor-derived tissues (Fig. 1a) . Consistent with the mRNA data, ACE2 and CD13 protein levels were remarkably lower in primary well-differentiated CF-HNECs ( Fig. 1b) . In contrast, no change in TMPRSS2 expression was observed between CF and nonCF primary HNECs, either in terms of mRNA or protein ( Fig. 1a and b) . To determine whether CFTR expression influences ACE2 expression, we utilized different cell models in which gene editing approaches were applied to modulate CFTR expression. In particular, we employed the human lung adenocarcinoma Calu-3 cell line in which CFTR was stably silenced by a short hairpin (sh)RNA (SH3 cells), as previously described 27 , the well-established CF bronchial epithelial cell line CFBE41o-, in which CFTR expression is almost undetectable, and cell lines derived from CFBE41o-cells expressing wild-type CFTR (CFBE41o-WT) or F508del-CFTR (CFBE41o-F508del). Finally, we used a human bronchial epithelial 16HBE14o-cell line expressing wild-type CFTR and edited using the CRISPR/Cas9 approach to obtain two supplemental cell lines carrying biallelic W1282X-CFTR or G542X-CFTR nonsense mutations.

The results unambiguously indicated that CFTR expression is associated with ACE2 expression (Fig. 1 ). In particular, CFTR-deficient SH3 cells displayed a remarkable reduction in ACE2 levels compared to both parental Calu-3 cells and mocktransfected cells, i.e. Alter 27 cells (Fig. 1d and e) . CD13 is not expressed in these cells.

In contrast, the introduction of both mutated F508del-CFTR and wild-type CFTR in CFBE41o-cells resulted in a substantial increase in ACE2 levels, accompanied by remarkable induction of CD13 protein expression ( Fig. 1f and g) . Then we assessed ACE2 expression in 16HBE14o-cells in which the CFTR sequence was edited using CRISPR/Cas9 technology. Consistent with the results from SH3 and Alter cells, we found that ACE2 protein synthesis was remarkably reduced in cells harboring nonsense-mutated CFTR, with undetectable levels of CFTR protein ( Fig. 1h and i) .

Thus, it seems that variations in ACE2 expression are not associated with specific CFTR genetic classes of defect, such as Class II folding defect of F508del-CFTR, but rather, are more widely related to defective CFTR protein. Moreover, a well-established inhibitor of CFTR ion flux, thiazolidinone CFTR(inh)-172 28 , partially reduced the expression of ACE2 ( Fig. 1h and i). Once again, CD13 protein levels were partially corepressed in these cellular models, particularly in the G542X-CFTR cell line ( Fig. 1h and i), confirming that CD13 expression is coregulated with ACE2 expression in airway epithelial cells, as previously demonstrated in other cell types 11 .

We therefore decided to investigate whether the subcellular distribution of the ACE2 receptor is dependent on CFTR expression, localization and function considering that the CFTR channel exists in a multiprotein complex that regulates CFTR channel activity but may also regulate the localization and function of other proteins on the plasma membrane [23] [24] [25] [26] . For this purpose, we investigated the subcellular distribution of ACE2 in different CFBE41o-cell models using immunofluorescence. In CFBE41o-cells, both CFTR and the ACE2 receptor were not localized to the plasma membrane (Fig.   2a ). The typical plasma membrane localization of the ACE2 receptor was instead observed in CFBE41o-(WT) cells expressing wild-type CFTR (Fig. 2a) . The expression of wild-type CFTR protein on the plasma membrane was strictly associated with the subcellular distribution of ACE2, as confirmed by Manders M1 and Pearson's coefficients, parameters sustaining the correlation between the intracellular localization of CFTR and ACE2 (Fig. 2b) . Interestingly, in CFBE41o-cells expressing F508del-CFTR, which encodes an unfolded CFTR protein that is primarily retained in the ER, ACE2 was almost entirely localized to the ER (Fig. 2a) . Once again, the colocalization of ACE2 with CFTR was validated by Manders M1 and Pearson's coefficients (Fig. 2b) .

The redistribution of ACE2 to the ER was confirmed by subcellular quantification, since the ratio between plasma membrane fluorescence and ER fluorescence was significantly reduced in CFBE41o-(F508del) cells compared to CFBE41o-(WT) and

16HBE14o-cells, where both CFTR and ACE2 proteins were primarily localized on the plasma membrane (Fig. 2b , III). Next, we examined whether ACE2 expression and localization could be only influenced by CFTR expression, or whether CFTR channel function could play a role. To this aim, we incubated 16HBE14o-and CFBE41o-(WT) cells re-expressing wild-type CFTR with CFTR(inh)-172 for 24 hours. Our data indicated that the prolonged functional block of ion efflux from CFTR does not lead to modification of the subcellular localization of ACE2 ( Fig. 2a and b) .

To exclude the possibility that mislocalization of the ACE2 receptor into the ER is due to alterations in the membrane trafficking pathway associated with the unfolded CFTR protein, we investigated the subcellular localization of CFTR-interactor NHERF1 29 . In the absence of CFTR expression, NHERF1 localizes closely to the plasma membrane in CFBE41o-cells (Fig. 3a) . NHERF1 normally binds to the CFTR channel through its PDZ domains. This interaction was indeed confirmed by the coefficients of colocalization in CFBE41o-(WT) cells re-expressing wild-type CFTR (Fig. 3b) .

However, the typical localization of NHERF1 was perturbed in CFBE41o-cells expressing the mutated F508del CFTR, encoding a CFTR protein that is primarily retained within the ER (Fig. 3b) . These results therefore support the hypothesis that the presence of a mutated CFTR channel, as well as the loss of CFTR expression, may induce mislocalization of the ACE2 receptor regardless of the membrane trafficking pathways.

In contrast to what has been observed for ACE2, the plasma membrane localization of CD13 was not perturbed by CFTR expression (Fig. 4) .

To confirm the role of CFTR in the SARS-CoV-2 life cycle, we employed two complementary strategies, use of a pharmacological inhibitor of CFTR function and a miRNA-based approach to specifically downregulate CFTR production, using the CFBE41o-and Calu-3 cell lines. The chronic effect of CFTR(inh)-172 on the extracellular release of SARS-CoV-2 from infected CFBE41o-(WT) cells expressing wild-type CFTR is shown in Fig. 5a . We utilized a previously validated methodology for in vitro viral infections 30 . The data obtained support the concept that inhibition of CFTR function is associated with a remarkable reduction in SARS-CoV-2 virulence (Fig. 5a ).

For comparison, the replication of SARS-CoV-2 has also been investigated in the mutant CFBE41o-(F508del) and parental CFBE41o-cell lines. Using these two cell lines, which harbor nonfunctional CFTR channels, the replication of SARS-CoV-2 was strongly suppressed (Fig. 5a ).

Regarding the miRNA-based strategy, our group and others have previously demonstrated that CFTR expression is under posttranscriptional control of different microRNAs [31] [32] [33] [34] . Since CFTR expression increased in response to antagomiR molecules against miR-145-5p 31, 32, 35 , the exposure of bronchial epithelial cells to this miRNA might lead to CFTR downregulation (see Fig. 5b for localization of miR-145-5p binding sites within the CFTR 3'UTR). In fact, four miR-145-5p binding sites are present in the 3'-UTR of CFTR (Fig. 5b) . Treatment of Calu-3 cells with premiR-145-5p significantly reduced the accumulation of CFTR mRNA (Fig. 5c ). Most importantly, treatment of Calu-3 cells with premiR145-5p remarkably reduced CFTR protein levels ( Fig. 5d and e). The conclusion of these experiments fully supports the concept that downregulation of CFTR can be achieved by a miRNA-mimicking strategy using premiR-145-5p.

We next assessed whether this treatment, performed on SARS-CoV-2-infected Calu-3 cells, is associated with alteration of the SARS-CoV-2 life cycle. The results revealed that pretreatment of Calu-3 cells with 100 nM premiR-145-5p is sufficient to dramatically inhibit SARS-CoV-2 viral production in a similar fashion to that observed by incubating Calu-3 cells with the CFTR(inh)-172 compound ( Fig. 5f and g) . We observed partial inhibition of mature CFTR protein expression upon prolonged incubation (72h) of CFTR(inh)-172 ( Fig. 5h and i) . This phenomenon has already been reported in other human cell lines, including K562 and SUP-B15 36 , and might explain the partial reduction of ACE2 observed upon CFTR(inh)-172 incubation shown in Fig. 1 . As expected from the data shown in Fig. 5c -e, western blot analysis of CFTR protein content in response to the different treatment conditions confirmed that CFTR synthesis was greatly inhibited by treatment with premiR145-5p ( Fig. 5h and i) .

In addition, we evaluated the effect of the ACE2 ligand SARS-CoV-2 S protein on IL-6 expression. Although CF lung pathology has been established as a proinflammatory condition featuring elevated levels of cytokines and chemokines, in particular IL-8 37 , some clinical evidence suggests that IL-6 levels are extremely low in sputum samples and bronchoalveolar lavage fluids obtained from CF patients [38] [39] [40] . Our data consistently showed that IL-6 mRNA expression was constitutively reduced in primary nasal and bronchial epithelial cells obtained from CF patients compared to healthy donor-derived tissues (Fig. 5j) . Interestingly, knockdown of CFTR expression in SH3 cells reduced expression of IL6 mRNA compared to mock-transfected Alter cells (Fig. 5j) . Most importantly, stimulation with the SARS-CoV-2 S protein led to a remarkable induction of IL-6 release in well-differentiated primary HNECs grown at the air-liquid interface derived from healthy donors but induced a very weak response in CF HNECs (Fig. 5k) . These data are in line with a recent report showing that the SARS-CoV-2 S protein increases IL-6 expression in macrophages isolated from nonCF subjects but not in CF cells 41 , strengthening the observations of the reduced expression and mislocalization of the ACE2 receptor in CF cells.

In conclusion, this work provides new insights into regulation of the expression and localization of ACE2 in relation to CFTR expression and function. This issue is of substantial interest for unraveling additional aspects in the pathogenesis of SARS-CoV-2 infection. Here, we show that CFTR expression and function are directly correlated with ACE2 expression and their interaction is necessary to place ACE2 receptor on the plasma membrane. Of note, our results show that CF airway epithelial cells constitutively express mislocalized and lower levels of ACE2 receptor than nonCF cells, which in turn leads to a reduction in SARS-CoV-2 infectivity. These results are in line with a previous report on TMEM16F 21 , strengthening the hypothesis that chloride channels are considerably involved in the SARS-CoV-2 biological cycle.

Given these findings, the use of chloride channel inhibitors or miRNAs against CFTR, such as miR-145-5p, is conceivable as a possible therapeutic strategy for preventing or limiting the adverse consequences of SARS-CoV-2 infection in humans.

All human samples were obtained and analyzed in accordance with the Declaration of Helsinki after written consent was obtained. All protocols were approved by the Ethics μ g/ml puromycin, as previously described 27 .

Transfection procedure of pre-miR-145 in Calu-3 cells was performed in 12-well plates using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Thermo Fischer Scientific) accordingly to manufacturer's instruction. Calu-3 cells were seeded at 2.5×10 5 /ml with 100 or 300 nM of hsa-miR-145-5p miRNA precursor (PM11480, Ambion, Thermo Fisher Scientific). After 72 h, cells were collected and total RNA was isolated using TRI Reagent™ (Sigma Aldrich) and immediately converted to cDNA. For the experiments with SARS-CoV-2 infection, cells were pre-treated with pre-miR-145-5p at 100nM for 48 hours before the infection.

Total RNA from HNECs, HBECs, Calu-3, SH3, Alter, CFBE41o-and 16HBE14o-cells was isolated using a High Pure RNA Isolation Kit (Roche, Mannheim, Germany) following the manufacturer's protocol. RNA concentration was determined using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and then stored at -80°C until use. A total of 500 ng of RNA was reverse transcribed to cDNA using a High-Capacity cDNA Reverse Transcription Kit with random primers (Thermo The analysis was performed using an AriaMx thermocycler (Agilent, Santa Clara, CA).

Changes in mRNA expression levels were calculated following normalization to the GAPDH reference gene, and relative quantification was performed using the comparative cycle threshold method.

In experiments employing the pre-miR-145, CFTR expression was analyzed by RT-qPCR using 300 ng of total RNA, which were reverse transcribed using the Taq (III) The histograms represent the ratio between plasma membrane fluorescence and endoplasmic reticulum (ER) fluorescence of ACE2 (black) and CFTR (gray). Data are mean ± SEM of 6 independent experiments. Normal distribution was tested by the Shapiro-Wilk test before running the Student's t test for paired data, which has been reported within the histograms (**p<0.01). and Pearson's (II) coefficients represent the correlation between the intracellular localization of CFTR and NHERF1, whereas (III) represents the ratio between plasma membrane fluorescence and endoplasmic reticulum (ER) fluorescence of NHERF1.

Data are mean ± SEM of 7 independent experiments. Normal distribution was tested by the Shapiro-Wilk test before running the Student's t test for paired data, which has been reported within the histograms (**p<0.01). experiments. Normal distribution was tested by the Shapiro-Wilk test before running the Student's t test for paired data, which has been reported within the histograms (*p<0.05, **p<0.01) 

Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis

Does cystic fibrosis constitute an advantage in COVID-19 infection?

Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: incidence and results of the national CF-COVID19-Spain survey

First wave of COVID-19 in French patients with cystic fibrosis

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2

and Is blocked by a clinically proven protease inhibitor

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

IL-6 and CD8+ T cell counts combined are an early predictor of inhospital mortality of patients with COVID-19

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Coronavirus receptors as immune modulators

Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions

Possible contribution of aminopeptidase N (APN/CD13) to migration and invasion of human osteosarcoma cell lines

CD13/aminopeptidase N is a negative regulator of mast cell activation

Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications

ECFS (A) H1N1 Study Group. Impact of the a (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis

Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study

SARS-CoV-2 infection in cystic fibrosis: a multicentre prospective study with a control group

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and

Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spikeinduced syncytia

Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain

Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator

Cystic fibrosis transmembrane conductance regulator-dependent up-regulation of Kir1

ROMK) renal K+ channels by the epithelial sodium channel

Cystic fibrosis transmembrane conductance regulator attaches tumor suppressor PTEN to the membrane and promotes anti Pseudomonas aeruginosa immunity

The cystic fibrosis transmembrane conductance regulator (CFTR) uses its C-terminus to regulate the A2B adenosine receptor

Prostaglandin E₂regulation of cystic fibrosis transmembrane conductance regulator activity and airway surface liquid volume requires gap junctional communication

Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion

An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton

TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection

A peptide nucleic acid against MicroRNA miR-145-5p enhances the expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in calu-3 cells

A peptide nucleic acid (PNA) masking the miR-145-5p binding site of the 3'UTR of the cystic fibrosis transmembrane conductance regulator ( CFTR) mRNA enhances CFTR expression in calu-3 cells

A peptide-nucleic acid targeting miR-335-5p enhances expression of cystic fibrosis transmembrane conductance regulator ( CFTR) gene with the possible involvement of the CFTR scaffolding protein NHERF1

Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells

Regulation of cystic fibrosis transmembrane conductance regulator by microRNA-145, -223, and -494 is altered in Δ F508 cystic fibrosis airway epithelium

High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A

Inflammation in cystic fibrosis: an update

Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6

Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis

Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy

Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages

Mitochondrial Ca 2+ -dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis

Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o-airway epithelial monolayers

The results are shown as the mean ± SEM from three independent experiments

c-e, Effect of premiR-145-5p treatment in Calu-3 cells. The effect on CFTR mRNA was verified by RT-qPCR (c). The effects on CFTR content were evaluated by western blot analysis (d). e, Densitometry analysis of four independent experiments

Results are reported as the mean ± SD from three independent experiments. h-i, Western blot analysis of CFTR in response to SARS-CoV-2 infection under the same conditions depicted in (f-g). j-k, Constitutive IL-6 expression is reduced in CF airway epithelial cells, and IL-6 release upon SARS-CoV-2 spike protein stimulation is reduced in CF. j, IL-6 mRNA was quantified by RT-qPCR in lysates obtained from differentiated HNEC cells obtained from a pool of 14 healthy donors (HNEC) versus 2 CF patients (CF-HNEC) homozygous for F508del CFTR or in primary HBEC obtained from four healthy control subjects versus four CF patients homozygous for F508del CFTR or in Alter cells versus SH3 cells. k, Quantification of IL-6 release by ELISA in cell culture supernatants obtained from well-differentiated HNECs and CF-HNECs. Cells were stimulated on both apical and basolateral sides with 1 μg/ml recombinant SARS-CoV-2 S protein for 12 h

We are grateful to the Cystic Fibrosis Foundation 

The authors declare no competing interests.